Literature DB >> 6467683

'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils.

D Caspi, M L Baltz, A Feinstein, E A Munn, M B Pepys.   

Abstract

Clearing of turbid amyloid A fibril containing agarose gels by human serum has been ascribed to 'amyloid degrading activity'. We report here that this optical phenomenon is not due to an enzymatic reaction, does not involve proteolysis of the fibril subunits and is not inhibited by sera of patients with AA amyloidosis. The extent of clearing correlates closely with the serum albumin concentration and, as previously reported by others, serum albumin itself causes clearing comparable to that of whole serum. Furthermore addition of albumin solutions to turbid aqueous suspensions of AA amyloid fibrils causes immediate clearing. Serum albumin is known to clarify turbid non-amyloid fibril containing gels and is used commercially to improve the optical properties of radial immunodiffusion plates. We therefore propose that this property of albumin, the mechanism of which is not yet understood, underlies the so called 'amyloid degrading activity' of human serum and the latter is not therefore likely to be of in vivo biological or clinical significance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467683      PMCID: PMC1536259     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

Review 3.  Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

4.  Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases.

Authors:  M D Benson; A S Cohen
Journal:  Arthritis Rheum       Date:  1979-01

5.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

6.  Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis.

Authors:  F C De Beer; R K Mallya; E A Fagan; J G Lanham; G R Hughes; M B Pepys
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

7.  Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis.

Authors:  C P Maury; A M Teppo
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

8.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

9.  Characteristics of the amyloid A fibril-degrading activity of human serum.

Authors:  A M Teppo; C P Maury; O Wegelius
Journal:  Scand J Immunol       Date:  1982-10       Impact factor: 3.487

10.  Degradation of amyloid by a serum component and inhibition of degradation.

Authors:  I Kedar; E Sohar; M Ravid
Journal:  J Lab Clin Med       Date:  1982-05
View more
  1 in total

1.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.